United Therapeutics Corporation (UTHR) Position Lessened by Profund Advisors LLC

Profund Advisors LLC trimmed its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 12.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,570 shares of the biotechnology company’s stock after selling 3,144 shares during the quarter. Profund Advisors LLC’s holdings in United Therapeutics Corporation were worth $2,798,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of UTHR. BlackRock Inc. increased its position in shares of United Therapeutics Corporation by 4,222.8% during the 1st quarter. BlackRock Inc. now owns 4,741,985 shares of the biotechnology company’s stock worth $641,969,000 after purchasing an additional 4,632,287 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of United Therapeutics Corporation by 144.0% during the 2nd quarter. Wells Fargo & Company MN now owns 730,634 shares of the biotechnology company’s stock worth $94,785,000 after purchasing an additional 431,210 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of United Therapeutics Corporation by 308.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 500,499 shares of the biotechnology company’s stock worth $64,930,000 after purchasing an additional 378,002 shares during the last quarter. AQR Capital Management LLC increased its position in shares of United Therapeutics Corporation by 27.8% during the 1st quarter. AQR Capital Management LLC now owns 1,736,357 shares of the biotechnology company’s stock worth $235,068,000 after purchasing an additional 377,395 shares during the last quarter. Finally, Schroder Investment Management Group increased its position in shares of United Therapeutics Corporation by 42.8% during the 2nd quarter. Schroder Investment Management Group now owns 1,091,675 shares of the biotechnology company’s stock worth $143,359,000 after purchasing an additional 327,360 shares during the last quarter.

In other news, Director Richard Giltner sold 3,490 shares of the stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $131.12, for a total value of $457,608.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 1,258 shares of the stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $122.08, for a total value of $153,576.64. Following the completion of the sale, the chief executive officer now owns 2,327 shares of the company’s stock, valued at approximately $284,080.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 25,198 shares of company stock valued at $3,281,816. Insiders own 7.80% of the company’s stock.

A number of analysts recently issued reports on the company. UBS AG reissued a “sell” rating and set a $106.00 price objective on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. ValuEngine raised United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 13th. BidaskClub downgraded United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Jefferies Group LLC reissued a “sell” rating and set a $105.00 price objective on shares of United Therapeutics Corporation in a research report on Friday, July 14th. Finally, Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Six research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $134.50.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Equities Focus and is owned by of Equities Focus. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.equitiesfocus.com/2017/09/17/united-therapeutics-corporation-uthr-position-lessened-by-profund-advisors-llc.html.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) traded down 0.18% during trading on Friday, hitting $120.79. The stock had a trading volume of 843,120 shares. The firm has a market cap of $5.25 billion, a price-to-earnings ratio of 14.01 and a beta of 1.52. The stock has a 50-day moving average of $128.92 and a 200 day moving average of $129.77. United Therapeutics Corporation has a 12-month low of $110.90 and a 12-month high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.61 by ($4.86). United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The company had revenue of $444.60 million during the quarter, compared to analyst estimates of $391.53 million. During the same quarter last year, the business posted $4.42 EPS. United Therapeutics Corporation’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, analysts predict that United Therapeutics Corporation will post $10.09 earnings per share for the current fiscal year.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply